A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials
Publication
, Conference
D'Amico, AV; Halabi, S; Vogelzang, NJ; Small, EJ
Published in: JOURNAL OF CLINICAL ONCOLOGY
July 15, 2004
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
July 15, 2004
Volume
22
Issue
14
Start / End Page
383S / 383S
Location
New Orleans, LA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
40th Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
D’Amico, A. V., Halabi, S., Vogelzang, N. J., & Small, E. J. (2004). A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 22, pp. 383S-383S). New Orleans, LA: AMER SOC CLINICAL ONCOLOGY.
D’Amico, A. V., S. Halabi, N. J. Vogelzang, and E. J. Small. “A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials.” In JOURNAL OF CLINICAL ONCOLOGY, 22:383S-383S. AMER SOC CLINICAL ONCOLOGY, 2004.
D’Amico AV, Halabi S, Vogelzang NJ, Small EJ. A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2004. p. 383S-383S.
D’Amico, A. V., et al. “A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials.” JOURNAL OF CLINICAL ONCOLOGY, vol. 22, no. 14, AMER SOC CLINICAL ONCOLOGY, 2004, pp. 383S-383S.
D’Amico AV, Halabi S, Vogelzang NJ, Small EJ. A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2004. p. 383S-383S.
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
July 15, 2004
Volume
22
Issue
14
Start / End Page
383S / 383S
Location
New Orleans, LA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
40th Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences